JP2012505917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505917A5 JP2012505917A5 JP2011532289A JP2011532289A JP2012505917A5 JP 2012505917 A5 JP2012505917 A5 JP 2012505917A5 JP 2011532289 A JP2011532289 A JP 2011532289A JP 2011532289 A JP2011532289 A JP 2011532289A JP 2012505917 A5 JP2012505917 A5 JP 2012505917A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- molecule
- water
- blood factor
- soluble polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000182 blood factors Drugs 0.000 claims description 125
- 229920003169 water-soluble polymer Polymers 0.000 claims description 47
- 239000002202 Polyethylene glycol Substances 0.000 claims description 33
- 229920001223 polyethylene glycol Polymers 0.000 claims description 33
- 125000005647 linker group Chemical group 0.000 claims description 28
- 108010054218 Factor VIII Proteins 0.000 claims description 25
- 102000001690 Factor VIII Human genes 0.000 claims description 25
- 229960000301 factor viii Drugs 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000003827 glycol group Chemical group 0.000 claims description 11
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 9
- 108010076282 Factor IX Proteins 0.000 claims description 7
- 229960004222 factor ix Drugs 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 208000015294 blood coagulation disease Diseases 0.000 claims description 6
- 108010054265 Factor VIIa Proteins 0.000 claims description 5
- 229940012414 factor viia Drugs 0.000 claims description 5
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims description 4
- 201000007219 factor XI deficiency Diseases 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 3
- 108010014172 Factor V Proteins 0.000 claims description 3
- 108010023321 Factor VII Proteins 0.000 claims description 3
- 108010014173 Factor X Proteins 0.000 claims description 3
- 108010074864 Factor XI Proteins 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 3
- 102000008946 Fibrinogen Human genes 0.000 claims description 3
- 108010094028 Prothrombin Proteins 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 102000002262 Thromboplastin Human genes 0.000 claims description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 3
- 229940012413 factor vii Drugs 0.000 claims description 3
- 229940012426 factor x Drugs 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 102100036537 von Willebrand factor Human genes 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- XLPJNCYCZORXHG-UHFFFAOYSA-N 1-morpholin-4-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCOCC1 XLPJNCYCZORXHG-UHFFFAOYSA-N 0.000 claims description 2
- 208000011403 Alexander disease Diseases 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000007371 Factor XIII Deficiency Diseases 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920001389 Poly(hydroxyalkylmethacrylamide) Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229950010030 dl-alanine Drugs 0.000 claims description 2
- 201000007386 factor VII deficiency Diseases 0.000 claims description 2
- 208000005376 factor X deficiency Diseases 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 208000009429 hemophilia B Diseases 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 claims description 2
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 229920001444 polymaleic acid Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10642408P | 2008-10-17 | 2008-10-17 | |
| US61/106,424 | 2008-10-17 | ||
| PCT/US2009/061023 WO2010045568A1 (en) | 2008-10-17 | 2009-10-16 | Modified blood factors comprising a low degree of water soluble polymer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057790A Division JP2015110676A (ja) | 2008-10-17 | 2015-03-20 | 低度の水溶性ポリマーを含む改変血液因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505917A JP2012505917A (ja) | 2012-03-08 |
| JP2012505917A5 true JP2012505917A5 (https=) | 2012-12-06 |
| JP5785872B2 JP5785872B2 (ja) | 2015-09-30 |
Family
ID=41650072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532289A Active JP5785872B2 (ja) | 2008-10-17 | 2009-10-16 | 低度の水溶性ポリマーを含む改変血液因子 |
| JP2015057790A Pending JP2015110676A (ja) | 2008-10-17 | 2015-03-20 | 低度の水溶性ポリマーを含む改変血液因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057790A Pending JP2015110676A (ja) | 2008-10-17 | 2015-03-20 | 低度の水溶性ポリマーを含む改変血液因子 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20100099616A1 (https=) |
| EP (3) | EP2349342B1 (https=) |
| JP (2) | JP5785872B2 (https=) |
| KR (2) | KR101929641B1 (https=) |
| AU (1) | AU2009305612B2 (https=) |
| BR (1) | BRPI0920259A8 (https=) |
| CA (1) | CA2738679A1 (https=) |
| CY (1) | CY1120921T1 (https=) |
| DK (1) | DK2349342T3 (https=) |
| ES (1) | ES2692172T3 (https=) |
| HR (1) | HRP20181454T1 (https=) |
| HU (1) | HUE039906T2 (https=) |
| LT (1) | LT2349342T (https=) |
| MX (1) | MX2011004085A (https=) |
| NZ (1) | NZ592688A (https=) |
| PL (1) | PL2349342T3 (https=) |
| PT (1) | PT2349342T (https=) |
| SI (1) | SI2349342T1 (https=) |
| SM (1) | SMT201800486T1 (https=) |
| WO (1) | WO2010045568A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106110311A (zh) * | 2009-07-27 | 2016-11-16 | 百深公司 | 凝血蛋白缀合物 |
| US20130040888A1 (en) | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| JP2013532176A (ja) * | 2010-07-15 | 2013-08-15 | ノヴォ ノルディスク アー／エス | 安定化させた第ｖｉｉｉ因子バリアント |
| RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
| MY190257A (en) * | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| SI2986313T1 (sl) | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US10238718B2 (en) | 2014-08-04 | 2019-03-26 | Csl Limited | Factor VIII formulation |
| ES2772933T3 (es) | 2015-03-06 | 2020-07-08 | CSL Behring Lengnau AG | Factor de von Willebrand modificado que tiene una semivida mejorada |
| JP6552286B2 (ja) * | 2015-06-05 | 2019-07-31 | 公立大学法人奈良県立医科大学 | 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット |
| CN114072420B (zh) | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
| JP7680442B2 (ja) | 2019-11-11 | 2025-05-20 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| AU6029594A (en) * | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6238908B1 (en) | 1995-06-07 | 2001-05-29 | Aastrom Biosciences, Inc. | Apparatus and method for maintaining and growth biological cells |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| RU2362807C2 (ru) * | 2002-06-21 | 2009-07-27 | Ново Нордиск Хелт Кэр Аг | Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция |
| JP2006517400A (ja) | 2002-12-19 | 2006-07-27 | ネクター セラピューティクス アラバマ，コーポレイション | シアノビリン変異体−ポリマー接合体 |
| WO2004075923A2 (en) * | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| KR20060003862A (ko) * | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | 수용성분기폴리머 및 그 접합체 |
| KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| KR101468345B1 (ko) * | 2004-11-12 | 2014-12-03 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| CA2591852A1 (en) * | 2004-12-27 | 2006-07-06 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| EP1891231A4 (en) * | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| CA2670618C (en) * | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| MX2009007145A (es) * | 2006-12-27 | 2009-08-27 | Nektar Therapeutics Al Corp | Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable. |
-
2009
- 2009-10-16 KR KR1020167022913A patent/KR101929641B1/ko active Active
- 2009-10-16 DK DK09752930.9T patent/DK2349342T3/en active
- 2009-10-16 CA CA2738679A patent/CA2738679A1/en not_active Abandoned
- 2009-10-16 AU AU2009305612A patent/AU2009305612B2/en active Active
- 2009-10-16 KR KR1020117011049A patent/KR20110071012A/ko not_active Ceased
- 2009-10-16 ES ES09752930.9T patent/ES2692172T3/es active Active
- 2009-10-16 EP EP09752930.9A patent/EP2349342B1/en active Active
- 2009-10-16 HU HUE09752930A patent/HUE039906T2/hu unknown
- 2009-10-16 WO PCT/US2009/061023 patent/WO2010045568A1/en not_active Ceased
- 2009-10-16 BR BRPI0920259A patent/BRPI0920259A8/pt not_active Application Discontinuation
- 2009-10-16 HR HRP20181454TT patent/HRP20181454T1/hr unknown
- 2009-10-16 SM SM20180486T patent/SMT201800486T1/it unknown
- 2009-10-16 EP EP18179965.1A patent/EP3437661A1/en not_active Withdrawn
- 2009-10-16 PL PL09752930T patent/PL2349342T3/pl unknown
- 2009-10-16 SI SI200931874T patent/SI2349342T1/sl unknown
- 2009-10-16 LT LTEP09752930.9T patent/LT2349342T/lt unknown
- 2009-10-16 NZ NZ592688A patent/NZ592688A/xx unknown
- 2009-10-16 EP EP19189998.8A patent/EP3620177A1/en not_active Withdrawn
- 2009-10-16 US US12/580,786 patent/US20100099616A1/en not_active Abandoned
- 2009-10-16 JP JP2011532289A patent/JP5785872B2/ja active Active
- 2009-10-16 MX MX2011004085A patent/MX2011004085A/es active IP Right Grant
- 2009-10-16 PT PT09752930T patent/PT2349342T/pt unknown
-
2011
- 2011-09-23 US US13/242,934 patent/US20120076749A1/en not_active Abandoned
-
2015
- 2015-03-20 JP JP2015057790A patent/JP2015110676A/ja active Pending
-
2016
- 2016-01-08 US US14/991,172 patent/US20160199503A1/en not_active Abandoned
-
2018
- 2018-09-24 CY CY181100982T patent/CY1120921T1/el unknown
- 2018-10-30 US US16/175,744 patent/US20190160178A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505917A5 (https=) | ||
| Yang et al. | Polysaccharide-based multifunctional hydrogel bio-adhesives for wound healing: a review | |
| Kadajji et al. | Water soluble polymers for pharmaceutical applications | |
| Das et al. | Modified biopolymer-dextrin based crosslinked hydrogels: application in controlled drug delivery | |
| Hasan et al. | Cellulose-based superabsorbent hydrogels | |
| Ebhodaghe | Hydrogel–based biopolymers for regenerative medicine applications: a critical review | |
| Wen et al. | A polysaccharide-based micelle-hydrogel synergistic therapy system for diabetes and vascular diabetes complications treatment | |
| AU2015242970B2 (en) | Glycopolysialylation of non-blood coagulation proteins | |
| Man et al. | An in situ catechol functionalized ε-polylysine/polyacrylamide hydrogel formed by hydrogen bonding recombination with high mechanical property for hemostasis | |
| Kundu et al. | Carboxymethyl cellulose–xylan hydrogel: synthesis, characterization, and in vitro release of vitamin B12 | |
| Aminabhavi et al. | Production of chitosan-based hydrogels for biomedical applications | |
| Himi et al. | Preparation and evaluation of stomach specific IPN hydrogels for oral drug delivery: a review | |
| Liu et al. | Superabsorbent Sponge and membrane prepared by polyelectrolyte complexation of Carboxymethyl cellulose/hydroxyethyl cellulose-Al3+ | |
| CN102406946B (zh) | 高分子阿霉素键合药及其制备方法 | |
| Rimmer | Biomedical hydrogels: biochemistry, manufacture and medical applications | |
| Patil | A review on polymer drug conjugate-what, why and how? | |
| Yang et al. | Bio-inspired lotus-fiber and mussel-based multifunctional hydrogels for wound healing: super-stretchability, self-healing, adhesion and antibacterial properties | |
| Iqbal et al. | Design and processing aspects of polymer and composite materials | |
| Oprea et al. | Synthesis and characterization of some cellulose/chondroitin sulphate hydrogels and their evaluation as carriers for drug delivery | |
| JP4925581B2 (ja) | 体液適合性および生体適合性を有する樹脂 | |
| MXPA01013276A (es) | Materiales biologicamente activos. | |
| Vaidya et al. | Bioconjugation of polymers: a novel platform for targeted drug delivery | |
| Taktak et al. | Production of LMWH-conjugated core/shell hydrogels encapsulating paclitaxel for transdermal delivery: In vitro and in vivo assessment | |
| Ali et al. | Smart hydrogel polymers for drug delivery | |
| CN106008964B (zh) | 一种水溶性的氨基酸嵌段共聚物及其制备方法和应用 |